🔎 Trials Near Me

Domov › Rak pljuč › Nebraska

Klinične študije za Rak pljuč v Nebraska

19 študij za Rak pljuč išče udeležence na lokacijah v Nebraska.

Mesta v Nebraska

Uradno besedilo študije (angleško)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Nebraska Medicine-Bellevue, Bellevue
  • Fred and Pamela Buffett Cancer Center - Kearney, Kearney
  • CHI Health Good Samaritan, Kearney
  • in še 5
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • in še 2
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Cancer Partners of Nebraska, Lincoln
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT04181060

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, LLC, Lincoln
  • NHO Support Center, Lincoln
  • Cancer Partners of Nebraska, Lincoln
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • Cancer Partners of Nebraska, Lincoln
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07489066

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
  • in še 5
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07063745

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Omaha
Vključevanje udeležencevFaza 2
Starost 18–95 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06712316

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Nebraska Hematology-Oncology (NHO), Lincoln
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT06712355

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • Nebraska Methodist Hospital, Omaha
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05624996

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Nebraska Cancer Specialists, Omaha
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT04198766

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT05242965

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Nebraska Cancer Specialist, Grand Island
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 30. jun. 2026 · NCT06162221

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • in še 3
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 26. jun. 2026 · NCT04614103

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • Nebraska Cancer Specialists, Omaha
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 14. maj 2026 · NCT06922591

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.